We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New Emails Suggest Former FDA Commissioner Hahn Intentionally Made False Claim About Convalescent Plasma

New Emails Suggest Former FDA Commissioner Hahn Intentionally Made False Claim About Convalescent Plasma

November 24, 2021

Did former FDA Commissioner Stephen Hahn cave to political pressure from the Trump Administration in authorizing hydroxychloroquine and convalescent plasma as treatments for COVID-19 even though there was scant evidence of their efficacy?

That’s what the House Select Subcommittee on the Coronavirus Crisis wants to know. On Monday, the committee sent a letter to Hahn asking him to sit for an interview Dec. 13.

By Dec. 6, the subcommittee said it wants to see all documents and communications in Hahn’s possession related to his involvement in the government’s response to the coronavirus, including his duties at the FDA or as a member of the White House Coronavirus Task Force.

The subcommittee said in the letter to Hahn that it had recently seen internal emails that show Hahn knew he was falsely claiming that convalescent plasma could increase survival by 35 percent overall when he spoke at the August 2020 press conference to announce the FDA’s emergency use authorization for convalescent plasma. In truth, it was a 35 percent relative reduction in mortality (DID, Aug. 26, 2020).

Hahn later apologized and said he misspoke. But the emails show he was planning to say “a 35 percent improvement in survival,” knowing it was inaccurate.

The subcommittee also has newly obtained texts between Hahn and Amy Abernethy, then principal deputy commissioner of Food and Drugs, discussing internal concerns about the safety of hydroxychloroquine.

Other issues the subcommittee wants to get to the bottom of: How much did the Trump administration interfere with the FDA’s authorization of coronavirus vaccines? And how much did the administration force herd immunity theories on public health officials, potentially leading to loss of life?

"Given the sustained campaigns to promote the use of dubious coronavirus treatments, the Select Subcommittee seeks to understand the full extent and impact of Trump Administration officials’ efforts to influence these FDA decisions,” said subcommittee chair Jim Clyburn (D-S.C.) in the letter to Hahn.

Read the full letter here:  www.fdanews.com/Subcommittee-Stephen-Hahn-letter.pdf. — Suz Redfearn

COVID-19

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • BioVentrix gets Expanded Access Approval for Left Ventricle Support System

  • FDA Approves Stemline’s Orserdu for Several Forms of Breast Cancer

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing